Summary of key Takeaways from the Interview with Mitzi Wasik on Mental Health & Neurology Posters
This interview with Mitzi Wasik,executive director of the AMCP Foundation,focuses on key themes and findings from posters presented at a recent conference (likely a managed care pharmacy conference). HereS a breakdown of the main points:
1. Real-World Data (RWD) is Crucial:
* RWD is bridging the gap between clinical trials and real-world application, providing payers with a clearer understanding of treatment impact and costs.
* RWD is vital for quantifying the economic and clinical burden of mental health and neurological conditions.
* However, RWD can be affected by systemic biases, leading too disparities in diagnosis and treatment.
2. Long-Acting Injectables (LAIs) are Beneficial:
* LAIs, especially antipsychotics, improve adherence and reduce acute care utilization compared to oral medications.
* LAIs are increasingly covered by benefit plans.
3. Utilization Management (UM) Needs Re-evaluation:
* Restrictive UM (prior authorization, step therapy) can lead to:
* Higher relapse rates
* Increased costs
* Worse outcomes
* Step therapy protocols can delay optimal care and increase downstream costs, especially in complex cases.
* More research is needed to refine UM criteria for diverse patient populations.
4. Disparities in care are a Major Concern:
* Meaningful disparities exist in diagnosis, treatment, and outcomes, particularly for:
* Women
* Low-SES populations
* Medicaid beneficiaries
* Systemic biases contribute to underdiagnosis and mismanagement, especially in women’s neurological health.
5. Timely Diagnosis is Key:
* Early diagnosis of conditions like MCI and Alzheimer’s disease is associated with:
* Lower costs (initial and long-term)
* Delayed institutionalization
* Improved survival
* Underdiagnosis and mismanagement lead to worse outcomes and higher costs.
* Early intervention in mental health is beneficial.
the posters highlighted the need for a more nuanced approach to managing care, leveraging RWD, addressing systemic biases, and optimizing UM strategies to ensure equitable access to timely and effective treatment for mental health and neurological conditions.
